Market News / Story
Kairos Pharma reports positive Phase 2 interim PFS data; median PFS 17.7 vs 2 months
·
Kairos Pharma reported statistically significant Phase 2 interim efficacy: median PFS 17.7 months with ENV-105 plus apalutamide vs 2 months with apalutamide alone (P=0.0008). Key Highlights: Interim analysis shows median PFS 17.7 months for ENV-105 + apalutamide vs 2 months for apalutamide alone (P=0.0008). Phase 2 protocol modified to enroll patients earlier after PSA rise following upfront androgen signaling inhibitor therapy. Modified design randomizes patients to…